开浦兰治疗新诊断儿童癫痫的临床疗效及安全性分析  

Efficacy and Safety of Left Levetiracetam( LEV ) for Therapy in Children with Newly Diagnosed Epilepsy

作　　者：谢扑松[1] 朱少波[1] 周火旺[1] 

机构地区：[1]福建医科大学附属漳州市医院儿科,漳州363000

出　　处：《海峡药学》2016年第4期106-107,共2页Strait Pharmaceutical Journal

摘　　要：目的探讨开浦兰治疗新诊断儿童癫痫的临床疗效和安全性。方法对2013年01月-2015年01月期间我院儿科新诊断80例癫痫患儿随机分为试验组和对照组各40例,试验组给予开浦兰单药治疗,对照组予德巴金单药治疗,治疗观察时间为半年,比较两者疗效及不良反应。结果试验组与对照组临床疗效及不良反应比较无显著变化,差异无统计意义（P〉0.05）。结论开浦兰治疗新诊断儿童癫痫的临床疗效及不良反应发生率与德巴金相当,可作为新诊断儿童癫痫一线药物。OBJECTIVE Efficacy and safety of left levetiracetam（ LEV） for therapy in children with newly diagnosed epilepsy was tested. METHODS New diagnosis of 80 cases of pediatric epilepsy children,from January2013 to January 2015,were randomly divided into trial group and control group（ n = 40）,The trial group was given LEV monotherapy,The control group was given VPA monotherapy,and Compare the curative effects and adverse reactions for half a year treatment observation. RESULTS Compared with the control group,there had no significant difference（ p〈0. 05）. CONCLUSION There was no difference of LEV and VPA for monotherapy in children with newly diagnosed epilepsy,left levetiracetam Can be used as first- line drugs for monotherapy in children with newly diagnosed epilepsy.

关 键 词：开浦兰 儿童癫痫 疗效 安全性 

分 类 号：R969.4[医药卫生—药理学]